144 related articles for article (PubMed ID: 21658657)
1. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab.
Martin SJ; Duvic M
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):286-8. PubMed ID: 21658657
[TBL] [Abstract][Full Text] [Related]
2. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
Witzig TE; Inwards DJ; Habermann TM; Dogan A; Kurtin PJ; Gross JB; Ananthamurthy A; Ristow KM; Garity JA
Mayo Clin Proc; 2007 Jun; 82(6):692-9. PubMed ID: 17550749
[TBL] [Abstract][Full Text] [Related]
3. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
4. Treatment of benign lymphoid hyperplasia of the orbit with rituximab.
Ho HH; Savar A; Samaniego F; Manning J; Kasyan A; Pro B; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2010; 26(1):11-3. PubMed ID: 20090476
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment.
Balode D; Beļajeva L; Ruesseler V; Quaas A; Lejniece S
Am J Case Rep; 2020 Jan; 21():e919616. PubMed ID: 31919337
[TBL] [Abstract][Full Text] [Related]
6. Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab.
Chen A; Hwang TN; Phan LT; McCulley TJ; Yoon MK
Middle East Afr J Ophthalmol; 2012 Oct; 19(4):432-5. PubMed ID: 23248552
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous lymphoid hyperplasia: a case report and brief review of the literature.
Lackey JN; Xia Y; Cho S; Sperling LC
Cutis; 2007 Jun; 79(6):445-8. PubMed ID: 17713147
[TBL] [Abstract][Full Text] [Related]
8. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
9. [Primary nodal follicular lymphoma with secondary cutaneous manifestations. First-line rituximab monotherapy].
Koch R; Sander CA
Hautarzt; 2010 Nov; 61(11):976-9. PubMed ID: 20221574
[TBL] [Abstract][Full Text] [Related]
10. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
[TBL] [Abstract][Full Text] [Related]
11. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
12. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.
Peñate Y; Hernández-Machín B; Pérez-Méndez LI; Santiago F; Rosales B; Servitje O; Estrach T; Fernández-Guarino M; Calzado L; Acebo E; Gallardo F; Salar A; Izu R; Ortiz-Romero PL; Pujol RM; Fernández-de-Misa R
Br J Dermatol; 2012 Jul; 167(1):174-9. PubMed ID: 22356294
[TBL] [Abstract][Full Text] [Related]
13. A review of 55 cases of cutaneous lymphoid hyperplasia: reassessment of the histopathologic findings leading to reclassification of 4 lesions as cutaneous marginal zone lymphoma and 19 as pseudolymphomatous folliculitis.
Arai E; Shimizu M; Hirose T
Hum Pathol; 2005 May; 36(5):505-11. PubMed ID: 15948117
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
[TBL] [Abstract][Full Text] [Related]
15. Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives.
Bezombes C; Fournié JJ; Laurent G
Mol Cancer Res; 2011 Nov; 9(11):1435-42. PubMed ID: 21921050
[TBL] [Abstract][Full Text] [Related]
16. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
Fernández-Guarino M; Ortiz-Romero PL; Fernández-Misa R; Montalbán C
Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in lymphomatoid granulomatosis.
Hernández-Marqués C; Lassaletta A; Torrelo A; López-Pino MÁ; Álvarez-Coca J; De Prada I; Hernández-Martín Á; Madero L
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e69-74. PubMed ID: 23337550
[TBL] [Abstract][Full Text] [Related]
19. [Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients].
Gellrich S; Muche JM; Pelzer K; Audring H; Sterry W
Hautarzt; 2001 Mar; 52(3):205-10. PubMed ID: 11284065
[TBL] [Abstract][Full Text] [Related]
20. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
